News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cyclacel
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
June 26, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
June 04, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
June 03, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 14, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
May 08, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
May 02, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 30, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
April 01, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 19, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 07, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
March 06, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
February 20, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
January 30, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
January 08, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
January 02, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
December 22, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
December 18, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Reverse Stock Split
December 12, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
November 30, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
November 28, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 13, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
November 07, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
August 09, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
August 03, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 11, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
May 04, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
May 03, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
March 07, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
March 06, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close